A detailed history of Mariner, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Mariner, LLC holds 2,998 shares of MDGL stock, worth $907,404. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,998
Previous 2,888 3.81%
Holding current value
$907,404
Previous $809,000 21.38%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$212.22 - $292.96 $23,344 - $32,225
110 Added 3.81%
2,998 $636,000
Q2 2024

Aug 13, 2024

BUY
$193.33 - $291.99 $49,299 - $74,457
255 Added 9.68%
2,888 $809,000
Q1 2024

May 15, 2024

BUY
$171.37 - $283.23 $234,948 - $388,308
1,371 Added 108.64%
2,633 $703,000
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $151,944 - $299,258
1,262 New
1,262 $292,000
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $42,624 - $216,474
730 New
730 $212,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.18B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.